As of 2025-07-04, the Intrinsic Value of Corbus Pharmaceuticals Holdings Inc (CRBP) is -20.64 USD. This CRBP valuation is based on the model Peter Lynch Fair Value. With the current market price of 7.71 USD, the upside of Corbus Pharmaceuticals Holdings Inc is -367.7%.

Is CRBP undervalued or overvalued?

Based on its market price of 7.71 USD and our intrinsic valuation, Corbus Pharmaceuticals Holdings Inc (CRBP) is overvalued by 367.7%.

Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.

7.71 USD

Stock Price

-20.64 USD

Intrinsic Value

Intrinsic Value Details

CRBP Intrinsic Value - Valuation Summary

	Range	Selected	Upside
a
Peter Lynch Fair Value	-20.64 - -20.64	-20.64	-367.72%
P/E Multiples	(86.45) - (101.72)	(109.19)	-1516.2%

CRBP Intrinsic Value - Peers Comparison

	Range	Selected	Upside
a
Abbvie Inc	59.01 - 369.54	115.21	-39.1%
Amgen Inc	184.69 - 828.17	326.99	9.6%
Regeneron Pharmaceuticals Inc	437.98 - 999.89	599.19	9.5%
ADMA Biologics Inc	11.63 - 44.41	18.36	0.5%
Outlook Therapeutics Inc	2.45 - 2.45	2.45	37.9%
Liminal BioSciences Inc	0.52 - 0.52	0.52	-93.9%

CRBP Intrinsic Value - Key Valuation Metrics

Market Cap (mil)	94
Beta	2.06
Outstanding shares (mil)	12
Enterprise Value (mil)	75

Market risk premium	5.1%
Cost of Equity	8.65%
Cost of Debt	5%
WACC	6.2%